1
|
Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Zirkelbach JF, Li Y, Liu J, Charlab R, Turcu FR, Liang D, Ghosh S, Roscoe D, Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR, Singh H. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clin Cancer Res 2020; 27:2130-2135. [PMID: 33239432 DOI: 10.1158/1078-0432.ccr-20-3558] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 10/26/2020] [Accepted: 11/20/2020] [Indexed: 11/16/2022]
Abstract
On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, and (iii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate). Approval was granted on the basis of the clinically important effects on the overall response rate (ORR) with prolonged duration of responses observed in a multicenter, open-label, multicohort clinical trial (LIBRETTO-001, NCT03157128) in patients whose tumors had RET alterations. ORRs within the approved patient populations ranged from 64% [95% confidence interval (CI), 54-73] in prior platinum-treated RET fusion-positive NSCLC to 100% (95% CI, 63-100) in systemic therapy-naïve RET fusion-positive thyroid cancer, with the majority of responders across indications demonstrating responses of at least 6 months. The product label includes warnings and precautions for hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, risk of impaired wound healing, and embryo-fetal toxicity. This is the first approval of a drug specifically for patients with RET alterations globally.
Collapse
Affiliation(s)
- Diana Bradford
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
| | - Erin Larkins
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Sirisha L Mushti
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Lisa Rodriguez
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Amy M Skinner
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Whitney S Helms
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Lauren S L Price
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Jeanne Fourie Zirkelbach
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Yangbing Li
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Jiang Liu
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Rosane Charlab
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Francisca Reyes Turcu
- Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Dun Liang
- Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Soma Ghosh
- Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Donna Roscoe
- Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Reena Philip
- Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Autumn Zack-Taylor
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Shenghui Tang
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Paul G Kluetz
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Julia A Beaver
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Richard Pazdur
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Marc R Theoret
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| | - Harpreet Singh
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.,Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland
| |
Collapse
|
2
|
Gabay O, Vicenty J, Zack-Taylor A, Tiffany L, Wunderlin G, Smith D, Reyes-Munoz L, Edwards V, Wu WW, Phue JN, Santana-Quintero L, Lam PV, Clouse KA. Exposure to TNF antagonist therapies induces variations of the gut microbiota in an in vivo model using healthy mice. Joint Bone Spine 2019; 87:175-178. [PMID: 31513888 DOI: 10.1016/j.jbspin.2019.08.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 08/29/2019] [Indexed: 12/26/2022]
Affiliation(s)
- Odile Gabay
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA.
| | - Jonathan Vicenty
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Autumn Zack-Taylor
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Linda Tiffany
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Grant Wunderlin
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Dylan Smith
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Lismari Reyes-Munoz
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Vivienne Edwards
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| | - Wells W Wu
- U.S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA
| | - Je-Nie Phue
- U.S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA
| | - Luis Santana-Quintero
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Hematology and Oncology Products, Silver Spring, MD, USA
| | - Phuc VinhNguyen Lam
- U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, HIVE, Silver Spring, MD, USA
| | - Kathleen A Clouse
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
| |
Collapse
|